<?xml version='1.0' encoding='utf-8'?>
<document id="16327334"><sentence text="Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results."><entity charOffset="0-9" id="DDI-PubMed.16327334.s1.e0" text="Efavirenz" /><entity charOffset="28-37" id="DDI-PubMed.16327334.s1.e1" text="efavirenz" /><entity charOffset="102-112" id="DDI-PubMed.16327334.s1.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.16327334.s1.e0" e2="DDI-PubMed.16327334.s1.e0" /><pair ddi="false" e1="DDI-PubMed.16327334.s1.e0" e2="DDI-PubMed.16327334.s1.e1" /><pair ddi="false" e1="DDI-PubMed.16327334.s1.e0" e2="DDI-PubMed.16327334.s1.e2" /><pair ddi="false" e1="DDI-PubMed.16327334.s1.e1" e2="DDI-PubMed.16327334.s1.e1" /><pair ddi="false" e1="DDI-PubMed.16327334.s1.e1" e2="DDI-PubMed.16327334.s1.e2" /></sentence><sentence text="The potential of drug-drug interaction between efavirenz and rifampicin is a major concern in the treatment of HIV and tuberculosis"><entity charOffset="47-56" id="DDI-PubMed.16327334.s2.e0" text="efavirenz" /><entity charOffset="61-71" id="DDI-PubMed.16327334.s2.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.16327334.s2.e0" e2="DDI-PubMed.16327334.s2.e0" /><pair ddi="false" e1="DDI-PubMed.16327334.s2.e0" e2="DDI-PubMed.16327334.s2.e1" /></sentence><sentence text=" The optimal efavirenz dosage is still unclear"><entity charOffset="13-22" id="DDI-PubMed.16327334.s3.e0" text="efavirenz" /></sentence><sentence text=" Our randomized control trial study recently reported the similar efavirenz level between efavirenz 600 and 800 mg/day in HIV-infected patients receiving rifampicin"><entity charOffset="66-75" id="DDI-PubMed.16327334.s4.e0" text="efavirenz" /><entity charOffset="154-164" id="DDI-PubMed.16327334.s4.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.16327334.s4.e0" e2="DDI-PubMed.16327334.s4.e0" /><pair ddi="false" e1="DDI-PubMed.16327334.s4.e0" e2="DDI-PubMed.16327334.s4.e1" /></sentence><sentence text=" We report the similar virological and immunological outcomes at 48 weeks between the two groups" /><sentence text=" Efavirenz 600 mg/day should be sufficient for concurrent use with rifamipicin"><entity charOffset="1-10" id="DDI-PubMed.16327334.s6.e0" text="Efavirenz" /><entity charOffset="67-78" id="DDI-PubMed.16327334.s6.e1" text="rifamipicin" /><pair ddi="false" e1="DDI-PubMed.16327334.s6.e0" e2="DDI-PubMed.16327334.s6.e0" /><pair ddi="false" e1="DDI-PubMed.16327334.s6.e0" e2="DDI-PubMed.16327334.s6.e1" /></sentence><sentence text="" /></document>